Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E2DL
|
|||
| Former ID |
DIB009559
|
|||
| Drug Name |
CDCA1-derived epitope peptide vaccine
|
|||
| Synonyms |
CDCA1-derived epitope peptide vaccine (HLA-A2402 restricted, prostate cancer); CDCA1-derived epitope peptide vaccine (prostate cancer), Iwate Medical University/Tokyo University/Oita University; Cell division cycle associated gene 1-derived epitope peptide vaccine (prostate cancer), Iwate Medical University/Tokyo University/Oita University; CDCA1-derived epitope peptide vaccine (HLA-A2402 restricted, prostate cancer), Iwate Medical University/Tokyo University/Oita University
Click to Show/Hide
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 1/2 | [1] | |
| Company |
Iwate Medical University
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01225471) Novel Peptide Vaccination for Patients With Advanced Prostate Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.